particle therapy was valued at USD 483.32 million in 2022!

The global particle therapy was valued at USD 483.32 million in 2022 and will reach USD 1.23 billion by 2030, registering a CAGR of 12.4% for the forecast period 2023-2030. The Driving factor of the Particle Therapy Market:Rising prevalence of cancerThe rate of cancer is increasing at a higher rate propelling the market for particle therapy across the globe. According to WHO cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Breast cancer has 2.26 million cases, lung cancer has 2.21 cases, colon and rectum cases has 1.93 million cases, prostate cancer has 1.41 million cases, and skin cancer has 1.20 million cases. Each year, approximately 4 lakh children develop cancer. Cervical cancer is the most common in 23 countries. Ionizing radiation, smoking, consumption of alcohol, drinking water contaminants (arsenic), infection from viruses, bacteria, and aging are the causes of cancer. The risk of specific cancer increases with age. Growth in the number of elderly patients is propelling the market.Advantages offered by particle therapy over traditional radiotherapyThere are a number of benefits to particle beam therapy over conventional photon therapy, particularly proton beam therapy. The market is expanding due to these benefits, particularly in developed economies where the adoption of advanced technology is strong. With the development of technologies like point scanning and motion tracking, the areas of applicability for particle beam treatment are also growing. Spot scans greatly minimize the dosage exposure to the healthy tissue around the target, and real-time motion tracking makes it possible for physicians to maintain the target in the beam's path and deliver regulated radiation therapy.Restraining Factor for the Particle Therapy Market:High cost and technological challenges:Installing particle treatment systems costs a lot of money and calls for extensive infrastructure. These machines need a lot of installation area since they are considerably larger than photon therapy systems (such as cyclotrons and synchrotrons). The particle treatment facility entails high costs for building, labor, and operating cost. As a result, only a few medical facilities in emerging and developing nations have access to advanced particle treatment equipment. The inability to distinguish the tumor from normal and healthy tissue and to clearly visualize the tumor is one of the main problems with particle treatment. However, it is highly challenging to irradiate just malignant growth without damaging adjacent tissues since tumors can change form on a regular basis. The radiologist places a safety buffer around the tumor to reduce this. These are the factors that are hampering the market.Impact of the COVID-19 Pandemic on the Particle Therapy Market:COVID-19's impact on the particle therapy market was positive. The post-pandemic condition in particle therapy is a rising need for consumer radiation therapy. According to data, COVID-19 affected the regular supply of proton therapy which leads to delays and cancellation of procedures. After the lockdown growth of the market increased due to the high prevalence of cancer. What is Particle Therapy?Particle therapy is a type of radiation therapy in which high-powered energy is used to treat cancer and some non-cancerous tumors. Radiation therapy using proton and carbon ions provides physical characteristics allowing for a volume conformal irradiation and a Reduction of the Integral dose to normal tissue. The particle device consists of a circular, accelerator, beamline, energy selection system, and patient application system. The particles are accelerated by high-frequency electromagnetic waves. As the protons move through the body, they slowly interact with electrons and release energy. The point where the highest energy release is known as the ‘Bragg peak’. A physician can designate the Bragg peak’s location, causing the most damage to the targeted tumor cells. The rise in clinical trials, advancement in radiotherapy, increase in the incidence of cancer, and a growing number of particle therapy centers provide lucrative growth to the particle therapy market.

全球粒子治疗市场在2022年估值达到4.8332亿美元，预计到2030年将达到12.3亿美元，在2023-2030年预测期间，其复合年增长率(CAGR)为12.4%。粒子治疗市场增长的主要驱动力为癌症发病率的上升：癌症的发病率正在以更高的速度增长，推动全球粒子治疗市场的增长。根据世界卫生组织的数据，癌症是全球死亡的主要原因，2020年导致了近1000万人死亡。乳腺癌有226万例，肺癌有221万例，结肠和直肠病例有193万例，前列腺癌有141万例，皮肤癌有120万例。每年，约有40万儿童患上癌症。在23个国家中，宫颈癌是最常见的。电离辐射、吸烟、酒精消费、饮用水污染物（如砷）、病毒、细菌感染以及衰老是癌症的成因。特定癌症的风险随着年龄的增长而增加。老年患者数量的增长正在推动市场的增长。粒子治疗相较于传统放射治疗的优点：相较于传统的光子治疗，特别是质子束治疗，粒子束治疗提供了许多优势。这些优势尤其是在技术采纳能力强的发达经济体中推动了市场的扩张。随着点扫描和运动跟踪等技术的发展，粒子束治疗的应用领域也在不断扩大。点扫描大大减少了靶区周围健康组织的剂量暴露，而实时运动跟踪使得医生能够维持靶区在束流路径中，并实施调控的放射治疗。粒子治疗市场限制因素：高昂的成本和技术挑战：安装粒子治疗系统需要大量资金和广泛的设施。这些设备由于比光子治疗系统（如回旋加速器和同步加速器）大得多，因此需要大量的安装空间。粒子治疗设施在建筑、劳动力和运营成本方面都较高。因此，只有少数新兴和发展中国家的医疗机构能够获得先进的粒子治疗设备。无法区分肿瘤与正常和健康组织，以及无法清晰可视化肿瘤是粒子治疗的主要问题之一。然而，由于肿瘤会定期改变形态，因此在照射恶性肿瘤而不损害相邻组织极具挑战性。放射科医生会在肿瘤周围放置安全缓冲区以减少这种风险。这些因素正在阻碍市场的发展。COVID-19大流行对粒子治疗市场的影响：COVID-19对粒子治疗市场的影响是积极的。大流行后的粒子治疗需求日益增长。据数据显示，COVID-19影响了质子治疗的正常供应，导致治疗延误和取消。由于癌症的高发病率，封锁后的市场增长。什么是粒子治疗？粒子治疗是一种使用高能量辐射治疗癌症和某些非癌症肿瘤的放射治疗方法。使用质子和碳离子进行放射治疗提供了物理特性，允许进行体积适形照射和减少对正常组织的总剂量。粒子治疗装置由圆形加速器、束流线、能量选择系统和患者应用系统组成。粒子通过高频电磁波加速。当质子穿过人体时，它们会逐渐与电子相互作用并释放能量。能量释放最高的点被称为‘布拉格峰’。医生可以指定‘布拉格峰’的位置，以对目标肿瘤细胞造成最大损害。临床试验的增加、放射治疗技术的进步、癌症发病率的上升以及粒子治疗中心的数量增加为粒子治疗市场提供了有利可图的成长空间。